Actively Recruiting
Non-invasive Brain Tumor Molecular Diagnostics and Monitoring
Led by The Institute of Molecular and Translational Medicine, Czech Republic · Updated on 2025-07-18
200
Participants Needed
1
Research Sites
573 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective multicenter study aims to enroll GBM patients who will undergo repeated assessments (preoperatively and 3 months post-surgery) to detect circulating tumor cells and analyze the transcriptomic profiles of EVs in their blood. The prognostic and monitoring significance of these biomarkers to disease course (assessing treatment efficacy, resistance incidence, tumor progression) will be evaluated. Concurrently, proteomic profiles typical of GBM will be analyzed in blood and ocular secretion samples from GBM patients, patients with low-grade gliomas, and patients without brain tumors to identify and validate novel protein biomarkers suitable for disease monitoring. Additionally, this study proposes an innovative approach to monitor GBM patients by investigating the presence of GBM-specific nucleic acid fragments in urine.
CONDITIONS
Official Title
Non-invasive Brain Tumor Molecular Diagnostics and Monitoring
Who Can Participate
Eligibility Criteria
You may qualify if you...
Adult patients with brain tumors -
You will not qualify if you...
No other cancer; no inflammatory disease
-
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Neurosurgery, University Hospital Olomouc
Olomouc, Czechia, 77900
Actively Recruiting
Research Team
J
Josef Srovnal, MD,PhD
CONTACT
O
Ondrej Kalita, MD,PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here